Clinical and multiomics changes with or without metformin during an 8-week very-low-carbohydrate intervention in PMOS patients: an exploratory randomized controlled trial

Dietary interventions, particularly carbohydrate-restricted approaches, improve metabolic and endocrine abnormalities in patients with polyendocrine metabolic ovarian syndrome (PMOS). However, whether metformin (MET) provides additional benefits when combined with intensive dietary intervention and how host metabolism and the gut microbiota respond at the molecular level remain unclear. In this pilot randomized controlled trial, overweight or obese women with PMOS (BMI 26–32 kg/m², aged 25–35 years) underwent an 8-week very-low-carbohydrate, low-calorie, high-protein dietary intervention (VLCD), with or without MET. Clinical parameters, plasma lipoproteins, untargeted serum metabolomics, and fecal metagenomics were assessed before and after the intervention. Between-group differences were evaluated using ANCOVA adjusted for baseline values. Among 38 randomized participants (20 VLCD, 18 VLCD + MET), 32 completed the 8-week assessment. Within-group reductions were observed in body weight, BMI, fasting insulin, HOMA-IR, and triglycerides, with no significant between-group differences in any outcome after adjustment. Both groups showed substantial lipoprotein remodeling, dominated by reductions in very low-density lipoprotein levels. The sets of metabolites meeting the within-group significance criteria partially overlapped between groups (the overlapped metabolites accounted for 48.1% and 56.9% in VLCD group and VLCD + MET group, respectively), with convergent alterations in bile acid-, lipid-, and amino acid-related pathways. The gut microbiota composition, diversity, and functional profiles changed minimally under both interventions. In this small, exploratory pilot trial, no statistically significant baseline-adjusted clinical differences between the interventions were detected. Within-group clinical and molecular changes provide hypotheses for further investigation but do not establish equivalent efficacy or metformin-specific effects. Larger trials with longer follow-up periods are needed to clarify the incremental benefit of adjunctive metformin.

Authors

Institutions

Publication Details

Journal
Nutrition Journal
Published
2026-11-12
DOI
https://doi.org/10.1186/s12937-026-01420-9
Primary Topic
Diet and metabolism studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical and multiomics changes with or without metformin during an 8-week very-low-carbohydrate intervention in PMOS patients: an exploratory randomized controlled trial

Huan Zhou, Qiang Huang, Guishan Chen, 李喜涛 et al.
Nutrition Journal
Diet and metabolism studies
article

Clinical and multiomics changes with or without metformin during an 8-week very-low-carbohydrate intervention in PMOS patients: an exploratory randomized controlled trial

Huan Zhou, Qiang Huang, Guishan Chen, 李喜涛, Man Chen, Guoshu Yin, Hong Lin, Qingxia Huang, Lichun Lu, Haibing Dai, Xiaoping Yang, Zhangran Chen, Fu Chen
article en

Abstract

Dietary interventions, particularly carbohydrate-restricted approaches, improve metabolic and endocrine abnormalities in patients with polyendocrine metabolic ovarian syndrome (PMOS). However, whether metformin (MET) provides additional benefits when combined with intensive dietary intervention and how host metabolism and the gut microbiota respond at the molecular level remain unclear. In this pilot randomized controlled trial, overweight or obese women with PMOS (BMI 26–32 kg/m², aged 25–35 years) underwent an 8-week very-low-carbohydrate, low-calorie, high-protein dietary intervention (VLCD), with or without MET. Clinical parameters, plasma lipoproteins, untargeted serum metabolomics, and fecal metagenomics were assessed before and after the intervention. Between-group differences were evaluated using ANCOVA adjusted for baseline values. Among 38 randomized participants (20 VLCD, 18 VLCD + MET), 32 completed the 8-week assessment. Within-group reductions were observed in body weight, BMI, fasting insulin, HOMA-IR, and triglycerides, with no significant between-group differences in any outcome after adjustment. Both groups showed substantial lipoprotein remodeling, dominated by reductions in very low-density lipoprotein levels. The sets of metabolites meeting the within-group significance criteria partially overlapped between groups (the overlapped metabolites accounted for 48.1% and 56.9% in VLCD group and VLCD + MET group, respectively), with convergent alterations in bile acid-, lipid-, and amino acid-related pathways. The gut microbiota composition, diversity, and functional profiles changed minimally under both interventions. In this small, exploratory pilot trial, no statistically significant baseline-adjusted clinical differences between the interventions were detected. Within-group clinical and molecular changes provide hypotheses for further investigation but do not establish equivalent efficacy or metformin-specific effects. Larger trials with longer follow-up periods are needed to clarify the incremental benefit of adjunctive metformin.

Nutrition Journal
Shantou University (CN), First Affiliated Hospital of Shantou University Medical College (CN), Panyu District Central Hospital (CN), Guangzhou Medical University (CN)
Wu Jieping Medical Foundation, Basic and Applied Basic Research Foundation of Guangdong Province
Good health and well-being, Zero hunger
Diet and metabolism studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon